B
BioNTech SE (BNTX)
NMS – Real vaqt narxi. Valyuta: USD
93.66
+0.32 (0.34%)
Yopilishda: May 12, 2026, 4:00 PM EDT
93.73
+0.07 (0.07%)
Bozor oldidan: May 13, 2026, 4:39 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
93.66
+0.32 (0.34%)
Yopilishda: May 12, 2026, 4:00 PM EDT
93.73
+0.07 (0.07%)
Bozor oldidan: May 13, 2026, 4:39 AM EDT
BioNTech SE, sho'ba korxonalari bilan birgalikda, Germaniyada immunoterapiyalarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya SARS-CoV-2 virusini davolash uchun mo'ljallangan mRNA vaksinasi bo'lgan BNT162 ni taklif etadi. Shuningdek, u III bosqich klinik tadqiqotlar doirasida onkologik dorilarni ishlab chiqadi, jumladan, metastatik mayda hujayrali bo'lmagan o'pka rakini davolash uchun Gotistobart, mayda hujayrali o'pka rakini va ilg'or/metastatik uchlik-negativ ko'krak bezi rakini davolash uchun Pumitamig, hamda metastatik ko'krak bezi rakini davolash uchun Trastuzumab pamirtecan va epirubicin va siklofosfamid; va II/III bosqich klinik tadqiqotlar doirasida dorilarni, masalan, inson papillomavirusi va bosh va bo'yinning yassi hujayrali karsinomasi uchun BNT113, shuningdek, metastatik kolorektal va mayda hujayrali bo'lmagan o'pka rakini davolash uchun Pumitamig. Bundan tashqari, kompaniya II bosqich klinik tadqiqotlar doirasida onkologik dorilarni ishlab chiqish bilan shug'ullanadi, jumladan, ilg'or mayda hujayrali bo'lmagan o'pka rakini davolash uchun BNT116, ko'plab qattiq o'smalar va ilg'or/metastatik ko'krak bezi rakini davolash uchun BNT326/YL202, ilg'or kolorektal rakni davolash uchun Autogene cevumeran va platina-rezistent tuxumdon rakini davolash uchun Gotistobart, shuningdek, glioblastoma, gepatotsellyulyar karsinoma, malign plevral mezotelioma, neyroendokrin neoplazmalar va metastatik oshqozon osti bezi kanalining adenokarsinomasini davolash uchun Pumitamig. Shuningdek, u mpox virusi uchun II bosqich klinik tadqiqotlarda bo'lgan BNT166; va yuqumli kasalliklar uchun I/II bosqich klinik tadqiqotlarda bo'lgan dorilarni ishlab chiqadi, jumladan, SARS-CoV-2 va gripp uchun BNT162 + BNT161, sil kasali uchun BNT164, bezgak uchun BNT165 va mpox uchun BNT166. Kompaniya 2008-yilda tashkil etilgan va bosh qarorgohi Germaniyaning Maynts shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal & Business Officer and Member of the Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board |
| Dr. Sierk Pötting Ph.D. | MD, COO & Member of Management Board |
| Dr. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board |
| Jasmina Alatovic | Vice President Corporate Communications |
| Mr. Douglas Maffei Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 6-K | form6-kadsrepurchaseprogra.htm |
| 2026-05-05 | 6-K | form6-kq12026quarterlyrepo.htm |
| 2026-04-13 | 6-K | form6-ktpamecdatasgo202613.htm |
| 2026-04-02 | 6-K | form6-kagm2026invitation2a.htm |
| 2026-04-01 | 20-F/A | bntx-20251231.htm |
| 2026-03-24 | 6-K | form6-kelcc24mar2026.htm |
| 2026-03-10 | 6-K | form6-kceocmo10mar2026.htm |
| 2026-03-10 | 20-F | bntx-20251231.htm |
| 2026-01-28 | 6-K | form6-kcpo28jan2026.htm |
| 2026-01-14 | 6-K | form6-kjpmpresentation13ja.htm |
| Vice President of Strategy & Investor Relations |
| Mr. Ramon Zapata-Gomez | CFO & Member of Management Board |
| Ms. Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board |
| Ms. Kylie Jimenez | Chief People Officer & Member of Management Board |
| Ms. Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting |